THE EVALUATION OF A CONTROL FOR AND A CONTROL F

Background

- Adherence to full non-occupational post-exposure prophylaxis (nPEP) regimen and follow up visits is poor in published literature
 - A review of individuals experiencing sexual assault reported only 40.3% completing 28 day course.
 - Attrition between ED and clinic for individuals in Boston seeking nPEP was 45.6% with only 23.9% of individuals having documented completion of 28 day course
- One important barrier to medication adherence is timely access to medications.
 - 4 week course of nPEP costs near \$4,000 without insurance and can remain unaffordable with insurance due to out of pocket costs
 - Many retail pharmacies do not keep antiretrovirals readily stocked
 - Some insurances require prior authorizations and/or restrict medications to be filled at mail-order pharmacies
- Previous PEP practice at this academic medical center includes:
 - ED consulting on-call ID pager for all potential PEP cases
 - 5 day starter kit provided to patient in ED
 - Patient scheduled for ID clinic follow up within 1-2 business days
 - If PEP is continued, script for remaining 23 days sent to pharmacy of patients choice
 - Follow up appointment and testing with ID clinic at 6 weeks and 3 months from exposure
- The aim of this pilot program was to determine the impact of pharmacist involvement on nPEP medication access and adherence.

Methods

- Single-center, retrospective review of 6 month period of pharmacist involvement with standardized intervention (4/1/2019-9/30/2019)
 - Compared to 6 month period where there was no pharmacist presence in ID clinic (2/1/2018-7/31/2019)
 - Occupational PEP (oPEP) cases were excluded
- Outcomes
 - Cost of nPEP regimen to patient
 - Documented completion of nPEP course
 - Attendance at initial ID clinic appointment
 - Medication access related interventions completed by pharmacist
- Descriptive statistics were used for analysis

Improving Patient Access to HIV Post-Exposure Prophylaxis with Pharmacist Involvement



	Pre Rph	Post Rph	
	(n=16)	(n= 27)	
Mean Age – yr (+/- SD)	29.5 +/- 11.0	29.7 +/- 9.6	
Exposure risk			
Consensual sex – no. (%)	7 (44)	12 (44)	
Needle stick – no. (%)	3 (19)	3 (11)	
Sexual assault – no. (%)	6 (38)	11 (41)	
Other*– no. (%)	0 (0)	1 (4)	
Male – no. (%)	9 (56)	16 (59)	
Ethnicity			
Black – no. (%)	4 (25)	7 (26)	
White – no. (%)	10 (63)	12 (44)	
Latino/Hispanic – no. (%)	1 (6)	5 (19)	
Asian/pacific islander – no. (%)	1 (6)	2 (7)	
Native American – no. (%)	0 (0)	1 (4)	
Regimen			
TDF/FTC + DTG – no. (%)	16 (100)	27 (100)	
TDF/FTC + RAL – no. (%)	1** (6)	0	



Contact Information Katlyn Grossman 800 Washington St #420 Boston, MA 02111 (617)636-8575 kgrossman@tuftsmedicalcenter.org

Results

	Pre-Rph (n=16)	Post Rph (n= 27)
clinic visit	8 (50)	17 (63)
rventions provided		
estigation – no. (%)	N/A	25 (93)
ounseling – no. (%)	N/A	15 (56)
erride* – no. (%)	N/A	4 (15)
no. (%)	N/A	9 (33)
tance program enrollment – no. (%)	N/A	0 (0)
letion Rx	8 (50)	18 (67)
mpletion of nPEP course – no. (%)	5 (31)	12 (44)
to patient - \$ (+/-SD)	475 +/- 1,232	2.10 +/- 3.25
gs - \$		2417.97
er pt - \$ (+/- SD)		142.23 +/- 350.65

• 100% of patients that came to initial clinic visit with pharmacist involvement picked up Rx same day from on site pharmacy compared to 63% prior to pharmacist involvement • One patient that filled at outside pharmacy had delay between starter pack and subsequent Rx with 1 day of missed medications

• No cases of gaps in medication with patients with pharmacist intervention

Conclusions

Pharmacist involvement was associated with substantial cost savings for nPEP patients Higher rates of patients picked up nPEP Rx's, attended clinic visits, and reported nPEP completion when pharmacist intervention was provided

Discussion

This pilot project identified a potential benefit from consistent pharmacist involvement in nPEP

Higher capture rate of prescriptions at in house pharmacy may generate greater revenue for medical center and allow for easier access to medications for patients Limitations: small sample size, single center, power to ensure statistical significance was not

Rates of documented nPEP completion from initial prescribing remain low • Next steps to identify ways to improve adherence to Rx and follow up visits

References

Cranston K, Alpren C, John B et al. Notes from the Field: HIV Diagnoses Among Persons Who Inject Drugs - Northeastern Massachusetts, 2015-2018. MMWR Morb Mortal Wkly Rep 2019;68:253-254.

Center for Disease Control and Prevention. Data Visualization: HIV Tansmissions in 2016. Vital Signs 2019.

https://www.cdc.gov/vitalsigns/end-hiv/data-visualization.html#info1. Accessed May 1 2019.

Chacko L, Ford N, Sbaiti M, Siddiqui R. Adherence to HIV post-exposure prophylaxis in victims of sexual assault: a systematic review and meta-analysis. Sex Transm Infect. 2012;88(5):335-341.

Bogoch UU, Scully EP, Zachary KC, et al. Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis. Clin Infect Dis. 2014;58(11):1618-24.

Center for Disease Control and Prevention, U.S. Department of Health and Human Services. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV – United States, 2016.